Memphis, TNNCT07801495Now EnrollingIRB Ready

Moderate to Severe Psoriatic Arthritis Clinical Trial in Memphis, TN

Access cutting-edge moderate to severe psoriatic arthritis treatment through this phase 2 clinical trial at a research site in Memphis. Study-provided care at no cost to qualified participants.

Sponsored by Novartis Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Memphis location

Preparing your pre-screening questions…

Expert Care in Memphis

Access moderate to severe psoriatic arthritis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related moderate to severe psoriatic arthritis treatment provided free

Apply for This Memphis Location

Check if you qualify for this moderate to severe psoriatic arthritis clinical trial in Memphis, TN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Memphis

    Convenient for TN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Memphis site if eligible
  4. 4Begin participation

About This Moderate to Severe Psoriatic Arthritis Study in Memphis

The purpose of this Phase 2a/b study is: 1. to evaluate the efficacy, safety and tolerability of DDY391 in participants with psoriatic arthritis (PsA). 2. to determine the dose-response relationship of DDY391 in participants with PsA to support dose selection for Phase 3.

Sponsor: Novartis Pharmaceuticals

Who Can Participate

Inclusion Criteria

Female or male participants at least 18 years of age.
Diagnosis of PsA and meeting classification criteria for Psoriatic arthritis (CASPAR) at screening.
Moderate to severe PsA at screening and baseline. Key

Exclusion Criteria

Presence of inflammatory conditions other than psoriasis or PsA including but not limited to those associated with arthralgia or arthritis (e.g., rheumatoid arthritis, systemic lupus erythematosus, scleroderma, sarcoidosis) or presence of fibromyalgia or osteoarthritis with articular symptoms.
Use of bDMARD treatment within 4 weeks or 5 half-lives of randomization, whichever is longer
Prior use of JAK inhibitors or TYK2 inhibitors (e.g., deucravacitinib). Prior use of apremilast is allowed but must not be taken within 4 weeks of baseline.
Previous treatment with any cell-depleting therapies, including but not limited to anti-CD20, unless ≥ 12 months prior to baseline.
History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months, carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).
Any active viral, bacterial or other infections at the time of screening or randomization, or history of recurrent clinically significant infection or of recurrent bacterial infections. Other protocol-defined inclusion/exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Memphis?

Yes, this clinical trial (NCT07801495) has an active research site in Memphis, TN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Moderate to Severe Psoriatic Arthritis Treatment Options in Memphis, TN

If you're searching for moderate to severe psoriatic arthritis treatment options in Memphis, TN, this clinical trial (NCT07801495) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Memphis research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced moderate to severe psoriatic arthritis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all moderate to severe psoriatic arthritis clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Memphis, TN

See all rheumatoid arthritis clinical trials recruiting in Memphis — not just this study.

Browse Rheumatoid Arthritis Trials in Memphis →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsPsoriasis TrialsPsoriatic Arthritis TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Memphis?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Memphis, TN